A Phase 2a Multicenter Single-Blind Placebo-Controlled Multiple Cohort Study Evaluating ABI-H2158-Containing Regimens in Chronic Hepatitis B Infection
Brief description of study
This study is being done to learn more about the safety and effects of an investigational drug called ABI- H2158, when taken in combination with entecavir (ETV) for the treatment of patients with chronic hepatitis B (CHB) who have never been treated for this infection or who have been treated for less than 4 weeks. This research study will also try to determine the best dose of ABI-H2158 to most effectively reduce hepatitis b virus (HBV) multiplication by testing how much of the HBV is in your blood during the dosing period.
Clinical Study Identifier: s20-00372
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
